Literature DB >> 10966795

Membrane-induced conformational change during the activation of HIV-1 gp41.

Y Kliger1, S G Peisajovich, R Blumenthal, Y Shai.   

Abstract

The human immunodeficiency virus type 1 gp41 ectodomain forms a three-hairpin protease-resistant core in the absence of membranes, namely, the putative gp41 fusion-active state. Here, we show that recombinant proteins corresponding to the ectodomain of gp41, but lacking the fusion peptide, bind membranes and consequently undergo a major conformational change. As a result, the protease-resistant core becomes susceptible to proteolytic digestion. Accordingly, synthetic peptides corresponding to the segments that construct this core bind the membrane. It is remarkable that the hetero-oligomer formed by these peptides dissociates upon binding to the membrane. These results are consistent with a model in which, after the three-hairpin conformation is formed, membrane binding induces opening of the gp41 core complex. We speculate that binding of the segments that constructed the core to the viral and cellular membranes could bring the membranes closer together and facilitate their merging. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966795     DOI: 10.1006/jmbi.2000.4004

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  14 in total

1.  Reversible stages of the low-pH-triggered conformational change in influenza virus hemagglutinin.

Authors:  Eugenia Leikina; Corinne Ramos; Ingrid Markovic; Joshua Zimmerberg; Leonid V Chernomordik
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

Review 2.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

3.  A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism.

Authors:  Roberto Pascual; Miguel R Moreno; José Villalaín
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

Authors:  Shidong Chu; Hardeep Kaur; Ariana Nemati; Joseph D Walsh; Vivian Partida; Shao-Qing Zhang; Miriam Gochin
Journal:  ACS Chem Biol       Date:  2015-02-17       Impact factor: 5.100

5.  Kinetically coupled folding of a single HIV-1 glycoprotein 41 complex in viral membrane fusion and inhibition.

Authors:  Junyi Jiao; Aleksander A Rebane; Lu Ma; Ying Gao; Yongli Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

6.  Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.

Authors:  Catherine M Finnegan; Werner Berg; George K Lewis; Anthony L DeVico
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Complete dissociation of the HIV-1 gp41 ectodomain and membrane proximal regions upon phospholipid binding.

Authors:  Julien Roche; John M Louis; Annie Aniana; Rodolfo Ghirlando; Ad Bax
Journal:  J Biomol NMR       Date:  2015-01-29       Impact factor: 2.835

8.  Dissociation of the trimeric gp41 ectodomain at the lipid-water interface suggests an active role in HIV-1 Env-mediated membrane fusion.

Authors:  Julien Roche; John M Louis; Alexander Grishaev; Jinfa Ying; Adriaan Bax
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

9.  Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.

Authors:  Michael J Root; Dean H Hamer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

10.  Hairpin folding of HIV gp41 abrogates lipid mixing function at physiologic pH and inhibits lipid mixing by exposed gp41 constructs.

Authors:  Kelly Sackett; Matthew J Nethercott; Yechiel Shai; David P Weliky
Journal:  Biochemistry       Date:  2009-03-31       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.